File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: LDH is an adverse prognostic factor independent of ISS in transplant-eligible myeloma patients receiving bortezomib-based induction regimens

TitleLDH is an adverse prognostic factor independent of ISS in transplant-eligible myeloma patients receiving bortezomib-based induction regimens
Authors
Issue Date2015
Citation
European Journal of Haematology, 2015, v. 94 n. 4, p. 330-335 How to Cite?
AbstractBACKGROUND: Serum lactate dehydrogenase (LDH) has been an adverse prognostic factor for myeloma but does not feature in the International Staging System (ISS). We examined if elevated serum LDH at diagnosis remains an adverse risk factor independent of ISS for survivals transplant-eligible myeloma patients receiving early/frontline bortezomib-based induction, followed by autologous stem cell transplantation (ASCT). PATIENTS: Seventy-seven transplant-eligible Chinese patients received three induction regimens [staged approach (N=25), PAD (N=19), VTD (N=33)], followed by ASCT and thalidomide maintenance. RESULTS: Five-year overall (OS) and event-free (EFS) survivals were 66.4% and 36.2%. There was no difference in demographics, CR/nCR rates post-induction or -ASCT, and survivals among patients induced by the three induction regimens. Elevated LDH was associated with male gender (p=0.006), ISS III (p=0.042) and serum β2-microglobulin (p=0.040). Univariate analysis showed that elevated LDH, ISS III, high β2-microglobulin and failure to attain CR/nCR post-ACST were risk factors adversely impacting both OS and EFS. Multivariate analysis showed that elevated LDH was the only factor impacting both OS (p=0.007) and EFS (p=0.008). CONCLUSION: In this uniformly treated cohort of transplant-eligible myeloma patients, elevated serum LDH is an adverse risk factor independent of ISS for both OS and EFS. Bortezomib-based induction/ASCT regimen had not abolished the adverse impact of elevated LDH. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/203074

 

DC FieldValueLanguage
dc.contributor.authorChim, JCSen_US
dc.contributor.authorSim, PYJen_US
dc.contributor.authorTam, Sen_US
dc.contributor.authorTse, EWCen_US
dc.contributor.authorLie, AKWen_US
dc.contributor.authorKwong, YLen_US
dc.date.accessioned2014-09-19T11:29:27Z-
dc.date.available2014-09-19T11:29:27Z-
dc.date.issued2015en_US
dc.identifier.citationEuropean Journal of Haematology, 2015, v. 94 n. 4, p. 330-335en_US
dc.identifier.urihttp://hdl.handle.net/10722/203074-
dc.description.abstractBACKGROUND: Serum lactate dehydrogenase (LDH) has been an adverse prognostic factor for myeloma but does not feature in the International Staging System (ISS). We examined if elevated serum LDH at diagnosis remains an adverse risk factor independent of ISS for survivals transplant-eligible myeloma patients receiving early/frontline bortezomib-based induction, followed by autologous stem cell transplantation (ASCT). PATIENTS: Seventy-seven transplant-eligible Chinese patients received three induction regimens [staged approach (N=25), PAD (N=19), VTD (N=33)], followed by ASCT and thalidomide maintenance. RESULTS: Five-year overall (OS) and event-free (EFS) survivals were 66.4% and 36.2%. There was no difference in demographics, CR/nCR rates post-induction or -ASCT, and survivals among patients induced by the three induction regimens. Elevated LDH was associated with male gender (p=0.006), ISS III (p=0.042) and serum β2-microglobulin (p=0.040). Univariate analysis showed that elevated LDH, ISS III, high β2-microglobulin and failure to attain CR/nCR post-ACST were risk factors adversely impacting both OS and EFS. Multivariate analysis showed that elevated LDH was the only factor impacting both OS (p=0.007) and EFS (p=0.008). CONCLUSION: In this uniformly treated cohort of transplant-eligible myeloma patients, elevated serum LDH is an adverse risk factor independent of ISS for both OS and EFS. Bortezomib-based induction/ASCT regimen had not abolished the adverse impact of elevated LDH. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.en_US
dc.languageengen_US
dc.relation.ispartofEuropean Journal of Haematologyen_US
dc.titleLDH is an adverse prognostic factor independent of ISS in transplant-eligible myeloma patients receiving bortezomib-based induction regimensen_US
dc.typeArticleen_US
dc.identifier.emailChim, JCS: jcschim@hku.hken_US
dc.identifier.emailSim, PYJ: jpysim@hku.hken_US
dc.identifier.emailTam, S: stam@hkucc.hku.hken_US
dc.identifier.emailTse, EWC: ewctse@hku.hken_US
dc.identifier.emailLie, AKW: akwlie@hkucc.hku.hken_US
dc.identifier.emailKwong, YL: ylkwong@hku.hken_US
dc.identifier.authorityChim, JCS=rp00408en_US
dc.identifier.authorityTse, EWC=rp00471en_US
dc.identifier.authorityKwong, YL=rp00358en_US
dc.identifier.doi10.1111/ejh.12434en_US
dc.identifier.hkuros236589en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats